Semaglutide for NAFLD/NASH

Candidate profile

Adults with diagnosed non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), confirmed by imaging (ultrasound, MRI-PDFF) or biopsy showing hepatic steatosis with or without fibrosis (stages F0-F3). Typical candidates have concurrent metabolic risk factors: elevated BMI, insulin resistance or type 2 diabetes, dyslipidemia, and elevated transaminases. The case is strongest when NAFLD coexists with obesity, since semaglutide addresses both hepatic fat and the underlying metabolic driver.

Not appropriate for decompensated cirrhosis (F4 with complications), alcohol-related liver disease, viral or autoimmune hepatitis, or other chronic liver disease causes. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome due to rodent thyroid C-cell tumor signals.

Approach

Semaglutide is a long-acting GLP-1 receptor agonist that reduces hepatic fat by addressing the metabolic root of NAFLD/NASH — caloric surplus, insulin resistance, and inflammatory signaling.

Key mechanistic pathways:

• Reduced de novo lipogenesis: GLP-1R activation downregulates SREBP-1c, decreasing hepatic triglyceride synthesis
• Enhanced lipid oxidation: Promotes fatty acid beta-oxidation, mobilizing stored intrahepatic fat
• Anti-inflammatory effects: GLP-1 receptors on Kupffer cells reduce TNF-alpha, IL-1beta, and IL-6 secretion, opposing the inflammatory cascade that converts steatosis to steatohepatitis
• Weight loss: At higher doses, 10-17% body weight reduction independently lowers hepatic fat (roughly 2-3% liver fat reduction per 1% body weight lost)
• Insulin sensitization: Improved hepatic insulin sensitivity reduces hyperinsulinemia-driven lipogenesis

Protocol design

Peptide: Semaglutide (Ozempic 0.25-2.0 mg; Wegovy 0.25-2.4 mg)

Route: Subcutaneous injection, once weekly

Escalation schedule:

• Weeks 1-4: 0.25 mg weekly (initiation/GI tolerability)
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly (Wegovy dosing)
• Week 17+: 2.4 mg weekly (maximum)

Injection site: Abdomen, thigh, or upper arm — rotate weekly.

Timing: Same day each week, any time, with or without food.

Duration: Minimum 24 weeks for hepatic fat assessment. The Newsome trial assessed outcomes at 72 weeks. Ongoing treatment is likely necessary, as hepatic fat reaccumulates if metabolic drivers persist.

GI management: Nausea is most common during escalation. Smaller meals, avoiding high-fat foods, and extending each dose step to 6-8 weeks can help. If nausea is severe, hold the current dose for an additional 4 weeks before escalating.

Expected timeline

Weeks 1-4 (0.25 mg): Minimal metabolic effect. Slight appetite decrease. Mild nausea in ~20% of users, typically resolving within 1-2 weeks.

Weeks 5-12 (0.5-1.0 mg): Weight loss begins (2-4 kg). Fasting glucose and HbA1c improve in diabetic patients. Transaminases may trend downward. MRI-PDFF unlikely to show dramatic changes yet.

Weeks 12-24 (1.0-2.4 mg): Meaningful hepatic fat reduction becomes measurable — 40-60% reduction from baseline in trials. FibroScan CAP scores decline. Weight loss reaches 8-12%. Transaminases often normalize.

Weeks 24-72: NASH histological improvement (lobular inflammation, hepatocyte ballooning resolution) demonstrated at 72 weeks in the Phase 2 trial. Fibrosis stabilization possible, though reversal is slow and inconsistent.

Monitoring markers

• MRI-PDFF at baseline, weeks 24 and 48 — most accurate non-invasive hepatic fat measure
• FibroScan at baseline and every 6 months — CAP for steatosis, kPa for fibrosis
• Liver transaminases (ALT, AST, GGT) at baseline, weeks 8, 16, 24, then quarterly
• Metabolic panel: Fasting glucose, HbA1c, fasting insulin, lipids — baseline and quarterly
• Body weight and waist circumference at each visit
• FIB-4 index and NAFLD Fibrosis Score at baseline and every 6 months
• Liver biopsy reserved for clinical uncertainty or trial enrollment

Evidence assessment

The landmark Phase 2 trial (Newsome et al., NEJM, 2021) randomized 320 patients with biopsy-confirmed NASH (F1-F3) to daily semaglutide (0.1, 0.2, or 0.4 mg) versus placebo. At 72 weeks, 59% on 0.4 mg daily achieved NASH resolution without fibrosis worsening, versus 17% on placebo.

Important caveats: the trial used daily dosing, not the weekly formulation. Weekly Ozempic/Wegovy dosing is extrapolated from PK equivalence and metabolic data. Phase 3 trials (ESSENCE program) evaluating weekly 2.4 mg for NASH with fibrosis are ongoing. Semaglutide is not yet FDA-approved specifically for NASH.

Liraglutide showed NASH resolution in 39% versus 9% placebo in the LEAN trial (Armstrong 2016, Lancet), establishing the GLP-1 class effect. Tirzepatide has shown up to 74% hepatic fat reduction by MRI-PDFF in the SYNERGY-NASH trial, suggesting incretin-based therapies as the most promising pharmacological NASH approach.

Important considerations

• Not standalone: Must complement dietary modification (Mediterranean diet has strongest NAFLD evidence), exercise (150+ min/week), and alcohol avoidance
• GI side effects: Nausea (40-45%), diarrhea (15-20%), vomiting (5-10%) during escalation — mostly mild and transient
• Gallbladder events: Increased cholelithiasis risk with rapid weight loss; monitor for biliary symptoms
• Pancreatitis: Rare but reported — discontinue if suspected
• Thyroid: FDA boxed warning for medullary thyroid carcinoma based on rodent data; mandates avoidance in MEN2/MTC-positive patients
• Rebound: Liver fat may return toward baseline after discontinuation, supporting sustained treatment or maintained lifestyle changes
• This article is for educational purposes only. NAFLD/NASH management requires medical supervision. Do not initiate, modify, or discontinue any treatment without consulting a qualified healthcare provider